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Abstract
Background: Trimethylaminuria (TMAU) is a genetic disorder whereby people cannot convert trimethylamine
(TMA) to its oxidized form (TMAO), a process that requires the liver enzyme FMO3. Loss-of-function variants in the
FMO3 gene are a known cause of TMAU. In addition to the inability to metabolize TMA precursors like choline,
patients often emit a characteristic odor because while TMAO is odorless, TMA has a fishy smell. The Monell
Chemical Senses Center is a research institute with a program to evaluate people with odor complaints for TMAU.
Methods: Here we evaluated ten subjects by (1) odor evaluation by a trained sensory panel, (2) analysis of their
urine concentration of TMA relative to TMAO before and after choline ingestion, and (3) whole exome sequencing
as well as subsequent variant analysis of all ten samples to investigate the genetics of TMAU.
Results: While all subjects reported they often emitted a fish-like odor, none had this malodor during sensory
evaluation. However, all were impaired in their ability to produce >90% TMAO/TMA in their urine and thus met the
criteria for TMAU. To probe for genetic causes, the exome of each subject was sequenced, and variants were
filtered by genes with a known (FMO3) or expected effect on TMA metabolism function (other oxidoreductases).
We filtered the remaining variants by allele frequency and predicated functional effects. We identified one subject
that had a rare loss-of-function FMO3 variant and six with more common decreased-function variants. In other
oxidoreductases genes, five subjects had four novel rare single-nucleotide polymorphisms as well as one rare
insertion/deletion. Novel in this context means no investigators have previously linked these variants to TMAU
although they are in dbSNP.
Conclusions: Thus, variants in genes other than FMO3 may cause TMAU and the genetic variants identified here
serve as a starting point for future studies of impaired TMA metabolism.
Backgrounds
The human body produces many chemicals that have an
odor. Sometimes these odors arise through normal cellu-
lar and metabolic processes, but sometimes they arise
from inborn errors of metabolism. One example of an
odorous chemical the body produces is trimethylamine
(TMA), which has the unpleasant odor of fish [1]. TMA is
derived from dietary choline and similar compounds (e.g.,
carnitine, betaine, taurine) found in many foods. When
choline is ingested, the gut bacteria cleave the TMA moi-
ety from it [2]. The free TMA is oxygenated by the human
liver enzyme flavin containing monooxygenase 3 (FMO3),
a member of the oxidoreductase class of enzymes, to the
odorless TMA-N-oxide (TMAO). Thus, under normal cir-
cumstances, choline ingestion does not result in body
odor through this pathway. However, people who have
genetic variants of the FMO3 gene that inactivate or lower
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its efficacy secrete the odorous TMA in urine, sweat and
other body fluids [3, 4].
Impaired trimethylamine metabolism is assessed by
tracking the ratio of TMAO to TMA and in the urine
after the person ingests a fixed amount of choline, a
challenge test [5]. While the syndrome is best known for
its fish-like body odor, in our experience, the odor is
episodic and may not be detectible at a single time point
[6] although oral odor, unrelated to TMA metabolism
(e.g., chronic halitosis) is common in these subjects as it
is in the general population [7]. The fish-like odor may
not be present during an assessment due to recent diet
(e.g., little or no choline) or other vicissitudes of life, e.g.,
[8–10]. Two other possibilities are 1) the transient form
of TMAU in children [11, 12], and 2) the odor might be
present but not detected because the assessor cannot
smell TMA [13] due to a specific anosmia in the human
population.
TMAU is a genetic disorder. Specifically variants in
the FMO3 gene are related to impaired trimethylamine
metabolism [3, 4, 14–19]. However, some people with
TMAU as defined by the choline challenge test do not
have any variants, either rare ones with total loss of
function or common ones (associated with less extreme
impairment) in this gene. Thus, variants in other genes
could contribute to this disorder, especially those genes
and their protein products within the pathway that
process trimethylamine in the same or a similar manner
as the FMO3 enzyme. At least two lines of evidence sup-
port this hypothesis. Variants of the DMGDH gene may
lead to a syndrome whereby subjects have a similar body
odor complaint (dimethylglycine dehydrogenase defi-
ciency; OMIM #605850, [20]) although the links between
odor and this genetic syndrome are speculative. In a
second line of evidence, variants in the pyridine
nucleotide-disulfide oxidoreductase domain 2 (PYROXD2)
gene is associated with the concentration of TMA in the
urine of healthy people [21, 22]. To determine whether
variants in novel genes contribute to this disorder, we
evaluated TMA metabolism by choline challenge, con-
ducted a sensory evaluation and sequenced the exome of
ten subjects with complaint of TMA-related body odor.
Whole exome sequencing (WES) examines protein-
coding regions of the entire human genome to identify
genetic variants, including single-nucleotide polymor-
phisms (SNPs), and small nucleotide insertions/deletions
of single or multiple nucleotides (indels). The amount of
genetic variation among all people is large, and separating
benign from potentially pathological variation is complex
[23]. Here we used three criteria to find variants of inter-
est. First, we looked for variations in genes previously as-
sociated with impaired TMA metabolism, e.g., the FMO3
gene. Second, we looked for the presence of a potentially
rare and pathogenic variant in other oxidoreductases with
functions similar to those of FMO3; and third, we evalu-
ated the in silico pathogenicity of each variant, its allele
frequency, and its presence shared by at least two subjects.
We reasoned that a rare variant with potential functional
significance observed in two or more subjects was more
likely to impair TMA metabolism. These three criteria
together helped to reduce the large set of observed varia-
tions to a manageable number worthy of further study.
Methods
Subject recruitment
We informed adult subjects with body odor complaints
who contacted the study investigators about participat-
ing in our ongoing sensory and genetic studies. Approxi-
mately 130 subjects made contact during an 8-year
period from 1999 to 2007 and we evaluated them for the
sensory and metabolic arms of the study. From this pool
of subjects, we chose ten at random for WES.
Choline challenge
For the choline challenge test, we instructed subjects to
fast from 10 pm the night before testing and collect their
first morning urine while at home. This collection was
done using a large, plastic container provided in ad-
vance; as previously described [5]. The container was
pre-loaded with 2 ml of 6 N HCl to convert free TMA
to its non-volatile hydrochloride salt. After the subjects
arrived in the lab and following the recording of first
sensory measures as described below, they ingested 5 g
choline dissolved in orange juice. Each subject took
three containers home and collected urine over the next
24 h, using one container for each 8-h period. Subjects
returned the following day with their urine. The volume
in each container was recorded and a 100 ml aliquot re-
moved to a smaller plastic container and frozen. These
urine samples were shipped on dry ice and assayed for
TMA and TMAO at the University of Colorado Health
Sciences Center following previously published proce-
dures [5], with steps for standard solution preparation,
water/urine test solution preparation for TMA analysis,
and choline loading analysis. We quantified the amount
of TMA for each 8-h sample; we measured the sample
with the highest concentration of TMA for TMAO. We
used the ratio of TMAO to TMA as the key outcome
measure: normal reference ranges are ≥0.90.
Sensory panel evaluation
For the sensory evaluation of body odor, subjects were
asked to come to the laboratory fasted and without
having brushed their teeth after 10 pm (22:00) the night
before; in addition, subjects were asked to refrain from
having applied any scented products (e.g., cosmetics and
deodorant products) for 3 days prior to testing. Upon
arrival at the laboratory, two trained sensory judges
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evaluated their breath, axillary and upper body odor with
quality descriptors (e.g., fishy or sulfurous) using
previously described procedures [7]. We repeated these
ratings the following morning, after the choline
challenge test.
Genomic DNA
When subjects returned their urine to the laboratory, they
gave a 20 ml sample of whole blood by venipuncture.
DNA was extracted (QIAamp DNA Mini Kit; Qiagen,
Valencia, CA, USA), quantified by spectrophotometry
(Nanodrop, Wilmington, DE, USA), and used in the ex-
ome analysis and for other follow-up genotyping.
WES and variant calling
Genomic DNA of 10ug each from ten subjects was part
of a large scale WES project of rare genetic diseases be-
tween the Center for Applied Genomics at the Children’s
Hospital of Philadelphia and BGI. Exomes were captured
using the Agilent SureSelect Human All Exon Kit V2
(Agilent Technologies, Santa Clara, CA, USA) and se-
quenced using the HiSeq 2000 machine (Illumina, San
Diego, CA, USA) with standard paired-end sequencing
protocol. We conducted subsequent bioinformatics as
previously described [24]. Briefly put, raw sequencing
reads were stored as FASTQ files and then aligned to
the human reference genome (UCSC hg19) with the
Burrows-Wheeler alignment [25]. Variant calling was
performed using the Genome Analysis Tool Kit (version
1.4) [26] followed by functional annotation using Annovar
[27] and SnpEff [28]. We identified all variant sites in a
larger set of exomes, and genotypes for any location with
one or more minor alleles were determined for all sub-
jects. Variant calling was also performed independently at
BGI as previously described [29], and high concordance of
results was obtained. For pathogenicity, each variant was
assigned two scores using algorithms implemented in
Phenotyping version 2 (PolyPhen-2) and Sorting Intoler-
ant From Tolerant (SIFT) [30, 31], respectively. Genes
whose products have oxidoreductase activity or that are in
the same pathway as FMO3 were identified through a
Gene Ontology website (N = 729) [32]. We also identified
variants where two or more subjects had the same rare
minor allele. The final filter was for the minor allele fre-
quency (MAF) <0.05 as reported in the 1000 Genomes
data set [33]. We identified variants that met the criteria
for potential pathogenicity and rarity, and shared by two
or more subjects.
Gene network analysis
Harnessing gene-gene/protein-protein network relation-
ships, we generated a list of genes that may interact with
FMO3, PYROXD2 and DMGDH, and investigated rare
deleterious variants within these genes. The interacting
partners were collected from the STRING database [34]
with default parameters below, setting 1) all possible active
interaction sources (including text mining, experiments,
databases, co-expression, neighborhood, gene fusion, and
co-occurrence); 2) minimum required interaction score of
0.4; 3) max number of interactors to show as 10.
Two genotyping methods to validate exome sequences
We partially Sanger sequenced DNA from each subjects
for the FMO3 gene and conducted Taqman genotyping
of the FMO3 and PYROXD2 variants to gauge WES reli-
ability. For Sanger sequencing, Exons 2–9 of the FMO3
gene were amplified by validated primers [3] and sub-
mitted for analysis to the DNA Sequencing Facility at
the University of Pennsylvania Perelman School of
Medicine. Sequencing reactions were performed in an
ABI GeneAmp 9700 thermal cycler, resolved with an
ABI 3730 DNA sequencer, and analyzed using ABI
Sequencing Analysis software, version 5.1 (Applied Bio-
systems, Foster City, CA, USA). Sequences were aligned
using the algorithms implemented in Sequencher (Gene
Codes Corporation, Ann Arbor, MI, USA), and the vari-
ants were identified [35] and matched against those ob-
tained by WES. We used Taqman methods to type four
specific variants, three in the FMO3 gene (rs2266780,
rs2266782, and rs2066532) and one in the PYROXD2
gene (rs7072216). The PYROXD2 variant is located in
the intronic region thus not captured by WES, but it
was reported in a previous paper for significant associ-
ation with TMA in urine [21]. Appropriate primers and
probes were cycled (StepOnePlus, Life Technologies,
Grand Island, NY), and variants were called using previ-
ously described methods [36].
Results
Odor evaluation and trimethylamine metabolism
As summarized in Table 1, of the ten subjects studied
here, eight were female and two were male. Six subjects
reported their race as Caucasian, and four as African
American. Table 1 also summarizes subject demograph-
ics and experimental outcomes. All subjects produced
abnormally low amounts of TMAO from choline and
met the criterion for TMAU, but the TMAO:TMA ratios
ranged widely, from 0.13 to 0.87 (normative values
>0.90). However, the sensory panel judged most subjects
to have unremarkable body odors, with one exception:
subject 98 had musty and damp odor. No subjects at the
time of evaluation had a fishy odor.
WES and analysis
From the larger sample set of the parent project (n = 669),
817,028 SNP variant sites and 75,781 indel sites were identi-
fied (Table 2 and Additional file 1: Table S1). We found sev-
enty percent of these variants in the homozygous state. Due
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to differences in sequencing coverage missing genotypes rate
varied among individuals and accounted for 15 to 23% of
SNP variant sites and 25 to 33% of total indel variant sites.
We identified one rare allele within the FMO3 gene.
This subject (#99) was heterozygous for a nonsense vari-
ant rs72549325 (chr1:g.171076936G > T; NM_00100229
4.2:c.442G > T; NP_001002294.1:p.Gly148Ter). We also
identified subjects with common variants. Five subjects
were heterozygous for rs2266782 (chr1:g.171076966G > A;
NM_001002294.2:c.472G >A; NP_001002294.1:p.Glu158
Lys), one subject was heterozygous for rs1736557 (chr1:g.
171080080G >A; NM_001002294.2:c.769G > A; NP_0010
02294.1:p.Val257Met) and one subject was heterozygous
for rs2266780 (chr1:g.171083242A >G; NM_001002294.
2:c.923A >G; NP_001002294.1:p.Glu308Gly). Although
common in the population, these three variants of the
FMO3 gene have been associated with impairments in
metabolism [37–39]. For the PYROXD2 gene, the allele of
interest is common and we found it in five subjects, three
of whom were homozygous. We summarize information
about these FMO3 and PYROXD2 gene variants in Table 3.
In addition, we list 23 more FMO3 rare gene variants that
have role in TMAU in Additional file 1: Table S2. We de-
tected none of these variants in the ten people studied here.
We next looked beyond the known genes and their
variants previously implicated in TMAU or TMA me-
tabolism for variants that are rare and predicted to have
reduced or abolished function. Specifically we focused
on novel variants of which at least one of the ten sub-
jects was homozygous for the alternative alleles, identify-
ing 94,535 SNPs and 5,212 indels. The pathogenicity of
these variants was predicted by algorithms implemented
in either PolyPhen-2 or SIFT; 1,867 SNPs and 163 indels
were predicted to be deleterious. Among these patho-
genic variants, 57 SNPs and four indels were in oxidore-
ductase pathways different from that of the FMO3 gene,
and four of these SNPs and one indel were rare, with
MAF < 0.05. Four of these five variants were found in
three subjects with the lowest TMAO:TMA ratios. In
addition, within other genes with no known function in
TMA metabolism, two subjects shared these rare vari-
ants for nine rare putatively pathogenic SNPs and one
rare putatively pathogenic indel. We depict the filtering
process for the variants in Fig. 1 and we list these results
in Table 4. We also conducted the gene-gene network
analysis inspired by STRING results, and similar variant
analysis was expanded to genes interacted with each of
FMO3 (Additional file 1: Figure S1), PYROXD2
(Additional file 1: Figure S2) and DMGDH (Additional
file 1: Figure S3). We found rare putatively pathogenic
SNPs in multiple genes interacting with DMGDH, in-
cluding BHMT2 (73% identical to the homologous
BHMT which is directly interacted with DMGDH),
SARDH and SHMT1 (Table 4). All of the subjects with
these SNPs were heterozygous. We found no rare dele-
terious variants from genes that are currently known to
interact with FMO3 or PYROXD2.
Table 1 Characteristics of subjects with body odor complaints
ID Age (yr) Sex Race TMAO: TMAa Fishy body odor Fishy oral odor Other, body odor Common oral odors
52 78 F C 0.13 None None None Pungent, sulfurousb
114 18 M AA 0.37 None None None Sulfurous/fecalb
122 64 F AA 0.47 None None None Fecal, pungentb
35 45 F C 0.54 None None None Mild sulfurousb
99 59 F AA 0.58 None None None Mild metallic, smoky
64 51 F C 0.61 None None None Mild
62 51 F AA 0.79 None None None Sulfurousb
113 47 M C 0.79 None None None Strong sulfurousb
98 44 F C 0.86 None None Mustyc Unremarkable
56 70 F C 0.87 None None None Unremarkable
ID subject identifier number, age age at assessment in years (yr), M male, F female, AA American of African descent, C Caucasian American of European descent.
Race/ethnicity was determined by self-report. aTable is sorted by TMAO:TMA ratio; Less than 0.90 is criterion for TMAU (i.e., reference > 0.90).bOral odor secondary
to plaque located on the posterior dorsal surface of the tongue. Plaque often contains odor-causing bacteria ([7] and references therein). cAlso described as ‘damp’
Table 2 Filtering of SNPs and indels
Number of variants SNPs Indels
Called in entire larger sample (n =669) 817,028 75,781
→ Found in all 10 TMAU subjects, with
at least one subject homozygous for the
minor allele
94,535 5,251
→ Pathogenic by SIFT or PolyPhen-2 1,867 163
→ Pathogenic in oxidoreductase pathways 57 4
→ Pathogenic in oxidoreductase pathways
and with MAF < 0.05
4 1
→ Pathogenic in genes with no known
choline metabolism function and
shared by 2 subjects
762 63
→ Pathogenic rare variant homozygous in
two subjects within genes with no known
choline metabolism function
9 1
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We show a summary of the number and type of gene
variants detected for each subject in Table 5. Six subjects
had variants in the FMO3 gene that reduce or abolish
function of the protein but four did not. However, those
subjects did have rare variants predicted to be deleteri-
ous in other genes that might account for their inability
to metabolize TMA. For instance, one subject (with #52)
had a very low ratio of TMAO:TMA (0.13) and while
she did not have any detectible variants in the FMO3
gene, she did have two rare variants in other genes an-
notated as oxidoreductases (CP and TXNDC2). Simi-
larly, another subject (#35) had no detectible FMO3
gene variants but was homozygous for the PYROXD2
variant that is associated with high TMA values in urine
among healthy people (rs7072216).
Sanger and Taqman sequencing compared with exome
results
When comparing the results of Sanger sequencing and Taq-
man genotyping versus WES, 29 of the 29 of the Sanger ge-
notypes matched and 30 out of 30 of the Taqman genotypes
matched (Additional file 1: Table S3 and S4). Overall, 60 of
60 genotypes matched for a concordance rate of 100%.
Discussion
All ten subjects studied had TMAU as defined by an im-
paired ability to metabolize choline during the challenge test
relative to the reference values for healthy populations.
Interestingly, only one of the subjects had a presumed loss-
of-function variant in the FMO3 gene (rs72549325), pre-
dicted to cause a truncated form of the FMO3 enzyme.
People who are heterozygous for this variant have reduced
caffeine metabolism compared with those with alternative
genotypes [40] and it may have a similar effect on TMA
metabolism. We detected several other common variants in
the FMO3 gene that can impair TMA metabolism and
might account, alone or in combination, for some or most
of the results of the choline challenge test. As one example,
subject 122 was a compound heterozygote for two common
variants in the FMO3 gene.
Two additional genes were previously but indirectly
implicated in TMAU: PYROXD2 and a DMGDH
(dimethylglycine dehydrogenase). Common variants of
the PYROXD2 gene are associated with small increases
of TMA in urine [21], and it is logical to assume that
variants exist that might be more disruptive and have
commensurately greater effects on TMA accumulation.
However, we observed no rare disruptive variants in this
study, although for the PYROXD2 gene, many subject
had the common variant identified in genome wide asso-
ciation studies of healthy people. This negative result for
rare variants does not preclude involvement of the PYR-
OXD2 gene in creating TMAU-related symptoms. WES
is designed to capture variants located at exons as well
as near splicing sites of the human genome, and has
limits in detecting genetic variants outside the exonic re-
gions, e.g. the flanking untranslated regions as well as
upstream and downstream regulatory regions. In
addition, for this gene and all others studied here, there
may have been loss-of-function variants we missed due
to the incomplete sequencing coverage/depth of
designed gene targets or limitations in evaluation of al-
lelic function. Likewise, none of the subjects in this
study showed loss-of-function DMGDH variants. How-
ever, we did identify rare deleterious variants in the
BHMT2, SARDH and SHMT1 genes, which directly
interact with DMGDH in the gene network and may
participate in the same pathway.
Table 3 Known rare and common pathogenic variants for TMAU observed in this study




















0.153b NP_001002294.1:p.Glu308Gly 98† [50]
PYROXD2 rs7072216c
chr10:g.100156853 T > C
NM_032709.2:c.625 + 249A > G
0.4012d Intronic 52†, 56†, 35§, 64§, 113§ [21]
aZygosity of samples: †heterozygous; §homozygous
bFrequency from ExAC database (http://exac.broadinstitute.org/)
cThis intronic variant is not seen in the exome data. We selected it based on literature search and genotyped it in the ten study samples
dFrequency from the 1000 Genomes Project (http://www.1000genomes.org/)
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While all subjects have TMAU as evinced by the cho-
line challenge test, none had a detectible fish-like odor
during testing. All were evaluated after an overnight fast
providing further credence to the role of choline restric-
tion, albeit difficult, as a means of symptom amelior-
ation. One of the frustrations of people with TMAU is
that their odor symptoms are episodic and may not be
detectible during medical visits, and because the odor
has come to be known as the cardinal feature of the
disease, this sometimes leads to delays in diagnosis. The
results of this study illustrate the point– the choline
challenge results indicated problems in TMA metabol-
ism and all the patients had sought treatment because of
body odor complaints. However, many subjects had hali-
tosis, which is not indicative of this specific metabolic
disease but is common in many populations [41], and
which may be confused with “body odor” unless one
performs sensory evaluation of the oral cavity and upper
Fig. 1 Filtering process to identify variants that could contribute to TMAU that are not in FMO3 or other genes previously and directly associated
with TMA metabolism
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body as we did here. Some people persistently complain
of body odor that is never detectable to others, a common
form of delusion called Olfactory Reference Syndrome
[42] which sometimes manifests itself with the mistaken
belief that the person has TMAU [43]. With the increased
ease of communication through the internet, the volume
of people with Olfactory Reference Syndrome can over-
whelm the small number of clinics and researchers who
study TMAU. Thus, the choline challenge test is useful in
deciding if the patient has TMAU because the fish-like
odor is not present consistently.
Malodor may not be the only medically and psycho-
logically important outcome of TMAU. Higher levels of
TMAO, the oxidized form of TMA, are associated with
increased incidence of atherosclerosis [44–46]. Thus, it
would be of interest to learn whether people with
TMAU have a lower incidence of this disease, e.g., to de-
termine whether people who produce less TMAO than
others may have a lower risk of cardiovascular disease.
Odor production may have an inverse relationship with
cardiovascular health benefits.
Low-choline diets are recommendation for TMAU
symptom management, but susceptible people can de-
velop organ damage if the diet is too low in choline [47].
Some people are susceptible because of their genotype
and others may be especially vulnerable because of their
particular gut microbiota which in some people can
over-convert choline into TMA [2]. If these particular
bacteria are present in high levels, they can deprive the
person of choline needed for other metabolic pathways
[48]. To circumvent this problem, investigators have
suggested that probiotics be used to treat TMAU, e.g.,
by converting TMA in the gut to an odorless compound,
although technical challenges currently preclude imme-
diate testing of this suggestion [49].
Table 4 Novel genetic variants with potential involvement in TMAU
Variants Chr Pos Gene MAF Subject IDa
SNPs in oxidoreductase pathways
rs61733458 3 148,916,215 CP 0.0110 52
rs34625494 17 41,002,169 AOC2 0.0032 62
rs72947591 18 9,887,167 TXNDC2 0.0179 52
rs116368403 19 41,600,254 CYP2A13 0.0046 122
Indels in oxidoreductase pathways
1 bp insertion 10 102,295,637 HIF1AN 0.0200 114
SNPs in DMGDH interactome
rs58580238 5 78,378,644 BHMT2 0.000154 56
rs35664470 9 136,584,082 SARDH 0.00692 99
rs78909145 17 18,243,524 SHMT1 0.00701 98
SNPs shared by at least two subjects
rs73891273 3 196,235,191 SMCO1 0.0445 62 & 99
rs77469804 6 110,679,450 METTL24 0.0262 114 & 122
rs77749341 7 149,462,317 ZNF467 0.0142 99 & 114
rs7091756 10 1,094,906 IDI1 0.0207 35 & 56
rs7956250 12 93,966,693 SOCS2 0.0257 99 & 122
rs55739813 15 41,803,754 LTK 0.0367 35 & 52
rs138735905 19 17,638,121 FAM129C 0.0193 64 & 98
rs114989947 22 17,265,194 XKR3 0.0344 99 & 113
rs41305431 X 103,495,552 ESX1 0.0266 113 & 114
Indels shared by at least two subjects
1 bp insertion — 1 158,533,298 OR6P1 0.0100 62 & 122
rs#: reference SNP identifier (does not apply to indels). Chr Chromosome, Pos
base pair position in map GRCh37/hg19, MAF minor allele frequency. aAll
subjects are homozygous for the minor allele
Table 5 Summary of number of deleterious genetic variants by subject
ID TMAO: TMA Total FMO3 PYROXD2 Oxido-reductase DMGDH interact Rare & shared
52 0.13 4 † §§ §
114 0.37 7 † §§ § §§*
122 0.47 7 †† § § §§§
35 0.54 4 †† §§
99 0.58 7 § § † §§§§
64 0.61 3 † § §
62 0.79 4 § § §§
113 0.79 3 † §*
98 0.86 5 †† § † §
56 0.87 5 † †† † §
Total = number of variants in all categories. † or § denotes the presence of a relevant allele in that category. Heterozygous = †, homozygous = §, hemizygous = *. FMO3
= variants in the FMO3 gene. PYROXD2 = variants in the PYROXD2 gene (see Table 3). Oxidoreductase = rare variants predicted to be deleterious in genes annotated for
oxidoreductase function (similar pathway as FMO3). DMGDH interact = rare variants predicted to be deleterious in genes that are predicted to interact with DMGDH, a
gene linked to similar symptoms as TMAU. Rare & shared = rare variants predicted to be deleterious that are shared between two subjects studied here (see Table 4).
Table is ordered by TMAO:TMA ratios, starting with the most severely impaired subject
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Conclusions
In summary, WES of ten subjects revealed genetic
variants that could potentially cause TMAU. Our results
suggest there could be multiple impairments of genes
and their protein products along this metabolic pathway
can cause accumulation of clinically significant amounts
of TMA. These genes provide a new avenue to pursue
when understanding the cause underlying body odor
complaints. Finally, our results further suggest that the
choline challenge test may be the most direct way to re-
veal putative deficits in oxidoreductase pathways, and
larger sample size coupled with more comprehensive
genetic methods such as whole genome sequencing will
facilitate the discovery of more TMAU causative/related
variants, either in the known genes e.g. FMO3 or in
novel genes implicated by gene-gene interactions.
Additional file
Additional file 1: Table S1. Variant distribution for exome sequencing.
Table S2. Known pathogenic alleles in FMO3 and PYROXD2 not detected
in these subjects. Table S3: Exome versus Sanger sequencing. Table S4:
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